Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer
the ONA take:
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT); furthermore, HRT can have a beneficial effect on their survival, according to a 24-year, phase III international trial.
Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust led the trial, which is the largest trial to investigate HRT’s effects on ovarian cancer survival.
The trial was set up in 1990 and followed 150 women with epithelial ovarian cancer. Half of the women were allocated to receive HRT during their treatment for up to 5 years, and half did not receive HRT. Overall survival in the two groups was compared at a point in 2012, 22 years after the trial began.
In the HRT arm of the trial, 53 of the 75 women (71%) had died, compared with 68 of the 75 women (91%) who had not taken HRT.
The researchers report these results are relevant to a large proportion of women with ovarian cancer because its treatment can trigger menopause.
“We were really happy to be able to show that HRT is safe for women with the most common type of ovarian cancer. Whether or not to have HRT is a very important decision for a large proportion of women with ovarian cancer, who will often have to undergo the menopause due to the cancer treatment at the same time as coping with a cancer diagnosis,” said study clinical lead Professor Ros Eeles, professor of Oncogenetics at The Institute of Cancer Research, London, and consultant at The Royal Marsden NHS Foundation Trust.
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|